

Consistently
delivering access to
PrSandoz®
Fingolimod

THIS PRODUCT
IS COVERED BY
Continium™
Patient Support Program
SEE BACK FOR DETAILS



- > Appearance of the capsule is identical to the branded product
- > Available in blisters of 28 capsules (two blisters of 14)
- > Calendar days printed on each blister to facilitate patient daily therapy compliance, same as the branded product

A generic equivalent
to **PrGilenya***

®Registered trademark owned or used under license by Sandoz Canada Inc.

*Registered trademark owned by its respective registrant.

Please consult the product monograph available at sandoz.ca/en/generics or obtain a copy by calling Sandoz Drug Information at 1-800-343-8839, ext. 4636.


SANDOZ A Novartis
Division

Sandoz Canada Inc. 110, rue de Lauzon, Boucherville (Québec) J4B 1E6
www.sandoz.ca

18-12-MKT003 exp 2021-03

PrSandoz® Fingolimod

A generic equivalent
to PrGilenya*

| Appearance (Actual size) | Strength | Format | UPC | DIN |
|---|----------|---|----------------|----------|
|  | 0.5 mg | Blister pack of 28 capsules (2 x 14 capsules) | 0 5751322048 7 | 02482606 |

Nonmedicinal ingredients (in alphabetical order):

Gelatin, magnesium stearate, mannitol, titanium dioxide, and yellow iron oxide.



Support you can trust

What is Sandoz Continuum™?

It is a free, simple, and personalized patient support program for PrSandoz® Fingolimod.

What does the program offer?

Our experienced team of patient access specialists provide:

- Financial assistance
- Reimbursement navigation
- Clinical services

Simple patient enrolment

The Sandoz Continuum™ enrolment form is available by calling us at 1-888-6-SANDOZ (726369), or online at sandoz.ca/en/psp.



For any questions, please contact Sandoz Continuum™ at 1-888-6-SANDOZ (726369).

® Registered trademark owned or used under license by Sandoz Canada Inc.

*Registered trademark owned by its respective registrant.

PrSandoz® Fingolimod (fingolimod) is indicated as monotherapy for the treatment of patients with the relapsing-remitting form of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the progression of physical disability. PrSandoz® Fingolimod is generally recommended in MS patients who have had an inadequate response to, or are unable to tolerate, one or more therapies for MS.

Please consult the product monograph available at sandoz.ca/en/generics or obtain a copy by calling Sandoz Drug Information at 1-800-343-8839, ext. 4636.